FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML

The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals

Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news